Pharmacy and Therapeutics Committee Meeting

Agenda
600 East Broad Street – 7th Floor Conference Rooms
Richmond, Virginia 23219
February 9, 2010 - 10:00 a.m.

DRAFT AGENDA

Welcome and Comments
Patrick Finnerty, DMAS Director

Call to Order
Randy Axelrod, M.D., Chairman

Approval of Minutes From October 22, 2009 Meeting
P&T Committee Members

PDL Management
P&T Committee Members

• Potential New Therapeutic Class Review (PDL Category)
  ♦ Insulins (Diabetes)
  ♦ Injectable Hypoglycemic Agents including incretin enhancers/mimetics (Diabetes)
  ♦ Androgenic Agents (Endocrine and Metabolic agents this is a potential new category)
  ♦ Platelet Inhibitors (Cardiac Medications)

• PDL Phase II – New Drug Review (Therapeutic Class)
  ♦ Twynsta® (Angiotension II Receptor Blockers and Calcium Channel Blocker Combination)

• PDL Phase II – Annual Review
  ♦ Analgesics
    • Long Acting Narcotics
    • Non-Steroidal Anti-Inflammatory Drugs (NSAID) (includes Cox-2 Inhibitors)
  ♦ Antibiotics/Anti-infective
    • 2nd and 3rd Generation Cephalosporins
    • 2nd and 3rd Generation Quinolones (systemic)
    • Ketolides
    • Macrolides
    • Oral Antifungals for Onychomycosis
    • Otic Quinolones
    • Topical Antibiotics
  ♦ Antivirals
    • Herpes Antivirals
    • Influenza Antivirals
    • Topical Antivirals
  ♦ Asthma- Allergy
    • Intranasal Antihistamines
    • Leukotriene Formation Inhibitors
    • Leukotriene Modifiers
  ♦ Central Nervous system
    • Anti-hyperkinetic/CNS Stimulants
    • Non-Ergot Dopamine Receptor Agonists
  ♦ Dermatologic
    • Benzoyl Peroxide and Clindamycin combinations
    • Topical Agents For Psoriasis
    • Topical Retinoids and combinations
• PDL Phase II – Annual Review (continued)

♦ **Immunologic agents**
  • Multiple Sclerosis Agents
  • Self Administered Drugs For Rheumatoid Arthritis

♦ **Ophthalmics**
  • Alpha-2 Adrenergic (for treatment of glaucoma)
  • Antihistamines
  • Beta-blockers (for treatment of glaucoma)
  • Carbonic Anhydrase Inhibitors (for treatment of glaucoma)
  • Mast Cell Stabilizers
  • Nonsteroidal Anti-Inflammatory (NSAID)
  • Prostaglandin Analogs (for treatment of glaucoma)
  • Quinolones and Macrolides

♦ **Oral Hypoglycemics**
  • 2nd Generation Sulfonyleureas
  • Alpha-Glucosidase Inhibitors
  • Biguanides including combination products
  • DPP-IV Inhibitors and combination products
  • Meglitinides
  • Thiazolidinediones and combination products

♦ **Osteoporosis**
  • Bisphosphonates
  • Calcitonins

♦ **Miscellaneous**
  • Serotonin Receptor Agonists (Triptans)

Confidential Meeting

• Pricing Information Discussion

Criteria Discussion of Potentially New Classes**
P&T Committee Members

Criteria Discussion of Phase I New Drugs**
P&T Committee Members

Criteria Discussion of PDL Phase II Drug Classes**
P&T Committee Members

Next Meeting – April 22, 2010
Randy Axelrod, M.D., Chairman

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.

Oral Presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on *only* the drug classes subject to PDL Phase II annual review, potential new drug classes, and specific new drugs in PDL Phase I classes listed on the Agenda. All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:

• PDL Phase II Annual Review – February 2009 to present
• New Drugs in PDL Phase I Drug Classes – February 2008 to present
• Potential New Drug Classes – February 2008 to present
No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to pdlinput@dmas.virginia.gov by **close of business Tuesday, January 19, 2010.**

**Written information/comments:** The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmas.virginia.gov by **close of business Tuesday, January 19, 2010.**